Biomea Fusion Reports Q1 2026 Net Loss $12.4M; Advances Clinical Trials
Biomea Fusion reported a net loss of $12.4 million for the first quarter ended March 31, 2026, a significant improvement from $29.3 million in the same period of 2025. The company also provided positive updates on its clinical programs, including the successful completion of chronic toxicology studies for icovamenib and the initiation of Phase II trials for icovamenib in type 2 diabetes. Initial 28-day weight reduction data for BMF-650 in obesity is anticipated in Q2 2026, and the company projects its cash runway into Q1 2027.
Key Highlights
- Net loss attributable to common stockholders was $12.4 million for Q1 2026, a decrease from $29.3 million in Q1 2025.
- Research and Development (R&D) expenses decreased to $9.1 million in Q1 2026 from $22.9 million in Q1 2025.
- General and Administrative (G&A) expenses decreased to $3.7 million in Q1 2026 from $6.8 million in Q1 2025.
- Cash, cash equivalents, and restricted cash totaled $45.1 million as of March 31, 2026.
- Cash runway is projected into the first quarter of 2027.
- Successfully completed chronic toxicology studies for icovamenib, supporting chronic clinical dosing.
- Topline 26-week data for Phase II COVALENT-211 and COVALENT-212 trials (T2D) expected in Q4 2026.
- Initial 28-day weight reduction data for Phase I GLP-131 trial (obesity) expected in Q2 2026.
Price Impact
More from BMEA
Biomea Fusion Q2 Net Loss Narrows to $8.3M; Going Concern Doubt Raised
Biomea Fusion Reports Q2 Net Loss $8.3M; Advances Diabetes & Obesity Trials
Biomea Fusion Icovamenib Data Shows T1D/T2D Benefits, Metabolic Health